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People & Ideas
A
s any CIA operative will tell you, 
the best defense is to know your 
enemy. Ari Helenius, veteran vi-
rologist, has spent the majority of his ca-
reer learning the sneaky infi  ltration tactics 
of human and animal foes such as infl  uen-
za, vaccinia, and herpes simplex virus.
And their tactics are many and varied. 
Helenius learned that Semliki Forest virus, 
for example, enters cells via endosomes 
and bursts into the cytoplasm when the en-
dosome’s acidic environment triggers fu-
sion of the virus’s membrane with that of 
the endosome (1). Vaccinia virus, on the 
other hand, fi  rst surfs the length of fi  lopodia 
to the cell surface and 
then impersonates cell de-
bris, tricking the host cell 
into gobbling it up (2).
Helenius’s work on 
viruses has also led him 
into studies on more gen-
eral aspects of cell biol-
ogy. He has published 
extensively on the topic 
of endocytosis (3) and 
also protein folding (4). 
Helenius is Professor of 
Biochemistry at the Federal Institute of 
Technology (ETH) in Zurich, and was the 
2007 recipient of the Marcel Benoist 
Prize, coined the “Swiss Nobel”.
STATESIDE TRAINING
How did you get started in science?
At the age of 17, I was chosen as an ex-
change student to go to the States. There was 
a program called the American Field Serv-
ice. It was originally started by the Quakers, 
who had set up an ambulance service during 
the First and Second World Wars.
After the Second World War, they de-
cided not to dismantle their organization 
but instead to start something that might 
help prevent future wars. The exchange 
program brings high school students from 
all around the world to study for one year in 
the States and to live with American fami-
lies. I think 70 or so students are chosen 
from Finland every year. I went in 1961 and 
stayed with a family in Pennsylvania.
It was an interesting phase for Ameri-
can education, because the Russians had 
recently succeeded in launching the Sputnik 
satellite, and the Americans were shocked 
by this event and poured huge amounts of 
money into science education.
I happened to be there at just the right 
time. My high school education in chem-
istry was extremely good. I was surround-
ed by a very enthusiastic group of students, 
and had a great teacher. I was totally taken 
by the whole thing, and decided to be-
come a chemist.
So I think the key thing that got me 
started in science was the excellence of 
the American high school education.
You don’t think this would have 
happened had you stayed in Finland?
No. I was always very interested in nature, 
but nothing scientifi  c. I grew up on a farm 
in Northern Finland and I was fi  xed on 
becoming either an agronomist or a forestry 
major, because that’s what one did up 
there. Also, the science teaching in school 
was uninspiring and out-of-date, so I was 
really turned off by that.
Where did you go to University?
I went to Helsinki University to study 
chemistry, but I was disappointed because 
I had learned so much in the States and 
felt that I wasn’t learning anything new. 
So I switched to biochemistry, which was 
new to me and more challenging.
Then an interesting thing happened. In 
my second year of studies I had a girl-
friend Majlen (who is now my wife), 
whose brother, Kai Simons, was a post-
doc at The Rockefeller University in New 
York. He returned to Helsinki after a year 
and started to put together a research 
group. He convinced me to join him.
Kai was a few years older than me, and I 
became his fi  rst undergraduate student and 
started working day and night in his labora-
tory. The work went well, and I ended up 
working with him for 13 years, fi  rst as an 
undergrad, then as a PhD student, then as a 
post-doc. In 1975 we moved together to the 
newly founded European Molecular Biolo-
gy Laboratory (EMBL) in Heidelberg.
It was like a family enterprise. Kai and 
his wife Carola had three children, and we 
had two. We built a house together, which 
was designed so we could take care of the 
children jointly. As all the parents were 
working full-time, we hired a child-minder 
to take care of the fi  ve  children.  Every 
working day, one of us would have to be 
back by 4:00 pm to take care of the chil-
dren. My day was Thursday. It’s a big prob-
lem juggling a scientifi  c career and a family, 
but by having this joint family arrangement 
it worked really well for everybody.
Like a mini commune.
Sort of. We had our own apartments and 
our own kitchens in that house, but there 
were doors between the apartments, so 
the children could come and go.
KNOWING THE ENEMY
What did you study with Kai?
I worked out how to use different deter-
gents to remove lipids from membranes 
and to analyze membrane proteins in solu-
tion. Little was known about membranes in 
those days, and practically nothing about 
membrane proteins. Detergents are now 
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used daily, of course, to solubilize mem-
branes and characterize, isolate, and purify 
membrane proteins. It’s interesting that the 
papers we produced in those early days, 
describing the methods, are the most cited 
papers I have produced.
What eventually made you decide to 
head for the States?
Although we had produced lots of good 
work in Kai’s laboratory, I was told that it 
wouldn’t be easy to fi  nd a job because I’d 
stayed in one laboratory for so long. And 
it was true; I had great diffi  culty. Luckily, 
I happened to meet George Palade—one 
of the fathers of cell biology. He was orig-
inally at Rockefeller, but when I met him 
he had moved to Yale. He took pity on me 
[laughs]. Actually, he wanted to expand 
his section at Yale and bring in someone 
who worked on viruses, which I did.
So you’d been working on viruses as 
well as membranes with Kai?
Exactly. For the membrane solubilization 
work we had been using a virus called 
Semliki Forest virus, because its mem-
brane coat is very simple. Then, when I 
moved to Yale I changed topics entirely 
and the question became, “How does a vi-
rus enter its host cells?” And that’s what 
I’m still working on.
Ira Mellman, your chief editor, and I 
started at Yale at the same time, and we 
shared a laboratory for 16 years. We 
worked on different topics, but the labora-
tory was one big joint space with every-
one and everything mixed together.
Aha, another commune!
Yes! I was very happy at Yale.
PROJECT ZURICH
So what precipitated your move to 
Zurich in 1995?
I became chairman of the department of 
cell biology at Yale, but somehow, even as 
chairman, it was hard to get funding to do 
what the department needed and also what 
I wanted to do in my own group. I wanted 
to start live cell microscopy so we could 
follow virus entry, but it was almost impos-
sible to buy the equipment when you’re in 
fragmentary grant systems. We needed 
something like $1.5 million to start an im-
aging facility, and to get that as a lump sum 
without having any record of being able to 
use the equipment was very hard.
You had to convince the funders you 
could use the equipment before they’d 
give you the money to buy it. Tricky.
Yeah. And I was unsuccessful in convinc-
ing them. But I was able to buy most of the 
equipment when I came here to ETH 
Zurich.  This place is quite special. I’m 
spending less time here worrying about 
money than I ever did in the United States.
There were many other reasons for 
moving, though. My wife and I had never 
really intended to stay forever in the 
States. So when I got this offer out of the 
blue, I thought, “Hey, why not?” Every 
time I have moved laboratories it’s been a 
boost in my scientifi   c productivity. So 
there’s much to be said for it.
What are the current projects in your lab?
One of the major projects has been to study 
how proteins fold in the living cell. This 
work came about because we worked a lot 
on infl  uenza virus entry into cells. A viral 
glycoprotein called hemaglutinin is produced 
in large amounts in the infected cell. We real-
ized that we had all these tools, antibodies, 
etc., to look at the synthesis and maturation 
of this protein, which thus provided the ideal 
means for looking at how proteins fold in 
general in vivo—because the virus borrows 
all the host cell machinery for this.
We’ve also been looking at Simian 
Virus 40 entry. We discovered that this virus 
uses a totally new type of endocytic path-
way. It goes from caveoliae to the endoplas-
mic reticulum. This prompted us to look 
at other viruses, and we found that there 
are many more endocytic pathways than 
we had ever thought of.
Are these newly discovered pathways 
unique to virus entry, or do they have 
a normal cellular function?
This question always comes up. The macro-
pinocytic pathway that vaccinia virus uses, 
as we described in a recent Science paper, is 
normally used by the cell to take up apop-
totic material. The clathrin-mediated uptake 
pathway used by many viruses is of course 
used by the cell for in-
ternalization of numer-
ous ligands, receptors, 
and plasma membrane 
components. As for the 
other pathways, we 
can’t be completely 
sure, but we are looking 
into it.
Another project we 
are doing now is to use 
siRNA screening to 
identify all the host 
proteins that a given 
virus needs to enter and infect a cell. We 
are doing this project together with two 
other groups here, that of Urs Greber, who 
used to be a post-doc in my laboratory, and 
Lucas Pelkmans, who used to be a gradu-
ate student in my laboratory.
With all this screening information, a 
huge amount of biology opens up. We can 
start to understand what the virus is doing. 
And in addition, the identifi  ed host pro-
teins are all potential antiviral targets.
It sounds like you’re generating a lot 
of data.
It is. It’s a lot of computing, a lot of bio-
informatics, and a lot of lists of genes. 
But it is clearly a direction in which virol-
ogy should be going—to focus on the host 
in addition to the pathogen.
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Semliki Forest virus sneaking into the cell via 
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